IBS & irritable bowel — all decisions

The Board denied service connection for bilateral hearing loss, IBS, left hip disability, right hip disability, left knee disability, and right knee disability. The effective date of March 7, 2022, was granted for the award of service connection for right lower extremity sciatica, and November 18, 2021, was granted for GERD.

The appeal for service connection for inguinal hernia, hypertension, left shoulder condition, and vision impairment was dismissed due to untimely filing of the notice of disagreement. The claims for headaches, OSA, IBS, and bilateral hearing loss were denied as there is no evidence linking these conditions to military service.

The Board granted an initial 30 percent disability rating for the service-connected irritable bowel syndrome (IBS) for the entire period on appeal.

The appeal for a higher disability rating for gall bladder removal with diarrhea (claimed as irritable bowel syndrome) was dismissed due to the Veteran's withdrawal of the appeal.

The Board denied service connection for irritable bowel syndrome, bilateral plantar fasciitis, and a temporomandibular disorder, including TMJ, as the evidence did not support current diagnoses or functional impairment during the pendency of the claims.

The Board granted service connection for right arm radiculopathy and an initial 30 percent evaluation for irritable bowel syndrome (IBS), while remanding the remaining claims.

The Board denied service connection for irritable bowel syndrome, gastroesophageal reflux disease, and a compensable rating for 5th digit strain of the left hand due to lack of evidence linking these conditions to the Veteran's military service.

The Board denied the veteran's claims for an initial compensable evaluation for sinusitis and irritable bowel syndrome (IBS), as well as a disability rating in excess of 10 percent for IBS prior to May 19, 2024.

The Board granted service connection for migraine headaches as secondary to the Veteran's service-connected PTSD and remanded several other claims for further development.

The Board granted service connection for chronic diarrhea (also claimed as irritable bowel syndrome) and remanded the claims for pleuritis, sinusitis, left wrist tendinopathy (tendinitis), and bilateral plantar fasciitis.

The Board granted an earlier effective date of July 24, 2021, for the grant of service connection for irritable bowel syndrome (IBS).

The Board remands the claims for service connection for bilateral hand tremors, respiratory insufficiency-dyspnea, chronic fatigue syndrome (CFS), irritable bowel syndrome (IBS), and hypertension to obtain further medical opinions.

The Board denied the veteran's claim for a disability evaluation in excess of 10 percent for non-allergic rhinitis, as there was no evidence of nasal polyps. The claims for IBS and fibromyalgia were remanded for further examination.

The Board denied service connection for irritable bowel syndrome (IBS) as the evidence did not support a finding that it began during active service or is related to an in-service injury.

The Board granted an effective date of August 10, 2022, but no earlier for entitlement to service connection for chronic sinusitis and allergic rhinitis. The Board denied an earlier effective date for irritable bowel syndrome and DEA benefits.

The Board granted service connection for lumbosacral strain, left and right lower extremity radiculopathy, irritable bowel syndrome (IBS), and a compensable disability rating for tension/common headaches.

The Board remands the claims for an initial compensable rating and earlier effective date for irritable bowel syndrome due to a need for a new VA examination.

The Board granted an initial 30 percent rating for irritable bowel syndrome (IBS), but no higher.

The Board denied a disability rating in excess of 70 percent for PTSD and remanded the claims for service connection for IBS and entitlement to TDIU.

The Board granted service connection for GERD and irritable bowel syndrome, both on the basis of secondary service connection. The effective date for asthma was set to April 28, 2022, and a 10 percent rating was assigned.